Saudi Journal of Gastroenterology
Home About us Instructions Ahead of print Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 374 


 
Table of Contents   
SYSTEMATIC REVIEW AND META-ANALYSIS  
Year : 2018  |  Volume : 24  |  Issue : 2  |  Page : 75-81
Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis


Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China

Click here for correspondence address and email

Date of Web Publication6-Apr-2018
 

   Abstract 


Background/Aims: A growing body of evidence has suggested that thiazolidinediones (TZDs) potentially reduce the risk of colorectal cancer (CRC). This study aimed to evaluate the effect of TZDs on CRC risk in patients with diabetes mellitus (DM).
Patients and Methods: A systematic search of electronic databases was performed for studies evaluating the exposure to TZDs and reporting CRC risk in diabetic patients. Pooled estimates with 95% confidence intervals (CIs) were estimated using fixed or random effects models.
Results: A total of 10 observational studies reporting more than 18,972 CRC cases in 2,470,768 DM patients were included. Meta-analysis showed a 9% reduction in CRC risk associated with TZDs use in all studies [relative risk (RR) =0.91, 95% CI = 0.84–0.99, P = 0.03] and cohort studies (RR = 0.89, 95% CI = 0.80–0.99, P = 0.04), respectively. However, such effect was not shown in case–control studies. In subgroup analyses, lower CRC risk was found in Asian population (RR = 0.40, 95% CI = 0.29–0.53, P = 0.00), and a trend toward lower CRC risk was observed in US population (RR = 0.94, 95% CI = 0.88–1.01, P = 0.08). CRC risk was significantly modified with non-pioglitazone TZD use (RR = 0.88, 95% CI = 0.82–0.95, P = 0.00), but not with pioglitazone use (RR = 0.95, 95% CI = 0.89–1.01, P = 0.11). No significant difference was observed with cancer site (colon or rectum). There was considerable inherent heterogeneity across studies, partly explained by study location.
Conclusions: This meta-analysis supports a protective association between TZDs use and CRC risk in patients with DM. Future well-designed prospective studies with larger cohorts would be needed to understand this association better.

Keywords: Colorectal cancer, diabetes mellitus, meta-analysis, thiazolidinediones

How to cite this article:
Liu Y, Jin PP, Sun XC, Hu TT. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis. Saudi J Gastroenterol 2018;24:75-81

How to cite this URL:
Liu Y, Jin PP, Sun XC, Hu TT. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis. Saudi J Gastroenterol [serial online] 2018 [cited 2018 Apr 22];24:75-81. Available from: http://www.saudijgastro.com/text.asp?2018/24/2/75/229480





   Introduction Top


Colorectal cancer (CRC) is the third most common malignancy worldwide with both prevalence and mortality increasing.[1] Diabetes mellitus (DM) is considered as an independent risk factor for CRC, with an approximately 30–40% higher risk as compared to non-DM patients.[2],[3] Diabetes promotes the development of CRC carcinogenesis through complex processes. The mechanisms underlying may possibly be related to hyperinsulinemia, hyperglycemia, or an obesity-associated chronic inflammation, which may contribute to an increased cellular proliferation and tumor formation.[4],[5],[6] Besides, high concentrations of insulin-like growth factor-1 (IGF-1) and the accumulation of β-catenin are also believed to play important roles in colorectal carcinogenesis in diabetes.[7],[8],[9]

Several preclinical studies have demonstrated that antidiabetic medications (ADMs) may modify the risk of multiple cancers. The insulin sensitizer thiazolidinediones (TZDs), known as peroxisome proliferator-activated receptors gamma (PPAR-γ) agonists, serve as one of the ADMs options to directly reduce insulin resistance in patients with DM. PPAR-γ belongs to the nuclear hormone receptor superfamily, which forms heterodimers with retinoid X receptor to bind to DNA response elements to exert its effects.[10] PPAR-γ is expressed at high levels in colon mucosa, adenocarcinoma, and human colon cancer cell lines.[11],[12] Previous studies have suggested that PPAR-γ agonists induce the differentiation and apoptosis of CRC cells, though some tumor suppression pathways, such as mTOR and LKB-1,[13],[14] reduce tumor growth in vitro and in vivo.[15],[16],[17],[18],[19] In addition to antiproliferative effects in CRC, TZDs may sensitize tumor cells to anticancer therapies.[20]

Although cancer-modifying effects are biologically plausible, data on the potential effect of TZDs are inconsistent. In earlier studies, some have shown an association between TZDs use and lower cancer risk among DM patients,[21],[22] while others have shown no beneficial effect.[23],[24]

Given the current evidence, there remains a lack of consensus regarding the effect of TZDs use on CRC risk. Thus, we performed a meta-analysis to examine the potential role of TZDs in influencing CRC susceptibility.


   Patients and Methods Top


Study identification

This study was performed according to the standard guidelines for meta-analyses and systematic reviews of observational studies.[25] PubMed, EMBASE, Cochrane Library, ISI Web of Knowledge were searched through April 2017 for observational studies investigating the association between TZDs and CRC risk, using the terms “thiazolidinediones,” “glitazones,” “troglitazone,” “pioglitazone,” “rosiglitazone,” “colorectal,” “colon,” “rectum,” “cancer,” “neoplasm,” and “risk.” The reference lists were also inspected for relevant studies.

Study selection and quality assessment

Eligible studies were included in the meta-analysis if they met the following criteria: (1) Full-text observational studies published in English, including cohort studies and case–control studies; (2) to compare TZDs with placebo or drugs other than TZDs; (3) with raw data on the association of TZDs use and CRC risk in DM patients, or report crude/adjusted estimates; (4) when multiple reports were published on the same population, the most recent/comprehensive publication was selected.

The quality of observational studies was assessed by Newcastle-Ottawa Scale (NOS), which included eight items scored by star. In this scale, observational studies were scored across three categories: selection of study groups, comparability of study groups, and ascertainment of the outcome of interest.[26]

Data extraction and synthesis

Study selections were performed independently by two of the authors (Y Liu and PP Jin). Disagreements were resolved by consensus. The following information were extracted:First author, publication year, study duration, study location, study design, cancer site, intervention, number of patients, and cancer incidence. The strength of the associations between treatments and outcomes was estimated by relative risk (RR) and 95% confidence interval (CI). Summary estimates of the RRs were derived using fixed-effects models (Mantel–Haenszel method) or random-effects models (DerSimonian and Laird method).[27] Adjusted estimates were pooled from the original studies if possible; otherwise, raw data were used to compute crude RRs. Heterogeneity between studies was assessed by Cochran Q-test. A P value of >0.10 for the Q-test indicated a lack of heterogeneity. I 2 statistic value of <30%, 30–60%, 61–75%, and >75% was suggestive of low, moderate, substantial, and considerable heterogeneity, respectively.[28] Heterogeneity was further explored by performing meta-regression analyses using method of moments, with P < 0.10 considered statistically significant.[29] Sensitivity analysis was performed by exclusion of each study. The presence of publication bias was assessed by Begg and Mazumdar adjusted rank correlation test (P < 0.05 indicated publication bias).[30] The Duval and Tweedie's trim and fill method was used for the estimation of results after correction for publication bias.[31] All meta-analyses were performed using STATA version 12.0 (Stata Corporation, Texas).


   Results Top


Eligible studies and quality assessment

A total of 10 full-text observational studies reporting more than 18,972 CRC cases in 2,470,768 patients with DM were included in the final analysis (7 cohort studies, 3 case–control studies).[23],[24],[32],[33],[34],[35],[36],[37],[38],[39] [Figure 1] shows the selection procedure. [Table 1] presents the main details of the selected studies. The NOS scores for observational studies ranged from 6 to 9 stars. The overall methodological quality of evidence was high.
Figure 1: Flowchart of literature search

Click here to view
Table 1: Main characteristics of the included studies

Click here to view


CRC risk in diabetic patients using TZDs

The main results of the meta-analysis are shown in [Table 2]. On meta-analysis of all observational studies that evaluated the risk of CRC with TZDs exposure in DM patients, the association was statistically significant (RR = 0.91, 95% CI = 0.84–0.99, P = 0.03) [Figure 2]. Considerable heterogeneity was found across studies (Pheterogeneity = 0.00, I 2 = 82.1%). Results were unchanged in cohort studies (n = 7 studies, more than 14,278 CRC cases in 2,223,780 patients with DM; RR = 0.89, 95% CI = 0.80–0.99, P = 0.04, I 2 = 86.9%).[24],[32],[35],[36],[37],[38],[39] However, such effects were not shown in case–control studies (n = 3 studies, 4,666 CRC cases in 246,988 patients with DM; RR = 0.94, 95% CI = 0.84–1.05, P = 0.28, I 2 = 31.9%).[23],[33],[34]
Table 2: Subgroup analysis of studies comparing the association between TZDs and CRC

Click here to view
Figure 2: Forest plot showing individual and pooled RRs (95% CIs) in studies comparing CRC risk in patients with DM on TZDs and controls

Click here to view


Subgroup analyses/sensitivity analyses

Subgroup analysis on study location did not show cancer-modifying effect of TZDs in Europe (n = 2 studies, more than 1,650 CRC cases in 361,722 patients with DM; RR = 0.96, 95% CI = 0.89–1.04, P = 0.34).[35],[37] A trend of protective effect was found in United States (US) (n = 7 studies, 16,971 CRC cases in 2,076,155 patients with DM; RR = 0.94, 95% CI = 0.88–1.01, P = 0.08),[23],[24],[32],[33],[34],[38],[39] although the association was not statistically significant. Only a cohort study from Asia showed a significant result (351 CRC cases in 32,891 patients with DM; RR = 0.40, 95% CI = 0.29–0.53, P = 0.00).[36] When referred to drug type, non-pioglitazone TZD showed a modest protective effect on CRC risk in diabetic patients (n = 2 studies, 12,268 CRC cases in 1,737,613 patients with DM; RR = 0.88, 95% CI = 0.82–0.95, P = 0.00);[37],[38] however, such effect was not found in pioglitazone group (n = 3 studies, 14,969 CRC cases in 1,974,120 patients with DM; RR = 0.95, 95% CI = 0.89–1.01, P = 0.11).[33],[37],[38] No significant difference was noted based on cancer site (For colon: n = 4 studies, more than 3,742 CRC cases in 660,664 patients with DM;[23],[33],[35],[38] RR = 1.00, 95% CI = 0.99–1.02, P = 0.61. For rectum: n = 3 studies, more than 1,017 CRC cases in 598,229 patients with DM;[33],[35],[38] RR = 0.98, 95% CI = 0.96–1.01, P = 0.23) [Table 2].

Due to significant heterogeneity, apart from using the random-effects model, further sensitivity analysis was performed. Exclusion of any study did not considerably alter the magnitude of summary estimate [Figure 3].
Figure 3: Sensitivity plot showing the effect of exclusion of any study on the magnitude of the summary estimate

Click here to view


The meta-regression analysis evaluating the regression of study location on log risk ratio showed significant result (Z = −2.08, P = 0.09); however, publication year (Z = 0.03, P = 0.98), study design (Z = −0.22, P = 0.83), cancer site (Z = 1.06, P = 0.34), drug type (Z = −0.96, P = 0.38), CRC cases > 1000 (Z = 0.37, P = 0.73), or NOS score >6 (Z = −0.55, P = 0.60) showed no significant results.

Publication bias

Begg's funnel plot was performed to assess the publication bias. The shape of the funnel plot did not reveal any evidence of asymmetry (P = 0.86) [Figure 4]. Using nonparametric Duval and Tweedie's trim and fill method, we found no additional undisclosed trials need be performed (data not shown).
Figure 4: Begg's funnel plot of publication bias test

Click here to view



   Discussion Top


In this comprehensive meta-analysis of 10 observational studies analyzing the cancer-modifying effect of TZDs in more than two million diabetic patients, we found TZDs were associated with a modest, yet statistically significant, protective association (an estimated 9% reduction) in CRC risk as compared to non-users of TZDs. The consistency of the results as shown in the sensitivity analysis and the lack of publication bias strengthened the results of this meta-analysis.

When restricting to the analysis on study population, we found the antineoplastic association of TZDs use and CRC risk was more pronounced in Asia than US (with a 60% reduction in Asia and a 6% reduction trend in US, respectively). The differences observed between the two regions should be interpreted with caution. First, different dietary habits and cultural behaviors may lead to the differential association in the two populations. Besides, a higher prevalence of central obesity is exhibited in some Asian populations, who are supposed to be more insulin resistant and more responsive to TZDs treatment as compared to Caucasians.[40],[41],[42] Moreover, only one study from Taiwan with 351 CRC cases in 32,891 DM patients was represented as an Asian population.[36] The results of other studies based on the Taiwan National Health Insurance Research Database (NHIRD) did not provide clear evidence of anti-CRC effect of TZDs.[22],[43],[44],[45] In view of the above-mentioned facts, more population-based studies assessing the effects of TZDs use on CRC risk in other Asian populations are needed to definitively clarify this issue.

As far as drug type is concerned, the apparent protection from malignancy conferred by non-pioglitazone TZD use (mainly rosiglitazone) was detectable in our study (a 12% reduction in CRC risk). On the other hand, pioglitazone did not protect from malignancy. The observed discrepancies between the two types of TZDs may be due to the differences at biologic level. Pharmacologically, rosiglitazone has PPAR-γ activity, which has shown antiproliferative, apoptotic-inducing, and differentiation-stimulating effects in different malignancies,[10] whereas pioglitazone has dual PPAR-α-γ activities, which have shown carcinogenic effects in animal models, especially for bladder cancer.[46],[47],[48],[49] The mediation of cancer initiation and progression through various pathways may also differ between the two TZDs.[50]

Pioglitazone continues to be recommended in current diabetes guidelines,[51] because concerns over bladder cancer conferred by pioglitazone have largely been allayed by recent evidence.[52],[53],[54] The side effects of rosiglitazone have limited its use, including weight gain, bone fracture, chronic edema, and heart failure.[55] Considering the positive consequences on CRC risk, the potential implications on the risk/benefit analysis of non-pioglitazone TZDs use should be revaluated.

We could not establish whether TZDs are differentially associated with risk of colon or rectal cancer. Comparisons that have been made for different cancer sites on CRC risk were not statistically significant.

The high statistical heterogeneity observed across studies could be partly explained by differences in study location. However, it could not be accounted for study design, cancer site, drug type, CRC cases, NOS score, or publication year. Besides, substantial heterogeneity was observed in European regions (Pheterogeneity = 0.01, I 2 = 87.2%), which may lead to some degree of detection bias.

Nevertheless, generally speaking, our meta-analysis should be interpreted with caution. First, patients in the comparator group (no TZDs) received a variety of ADMs, including insulin, insulin analogs, sulfonylureas, metformin, or other hypoglycemia agents, which may have inherent cancer-modifying effects. For example, insulin or sulfonylurea has been reported to be associated with an increased risk of CRC, whereas metformin may be correlated with a decreased CRC risk.[56] This may result in an overestimation or underestimation of the magnitude of effect on CRC. Second, all studies did not adjust for the same confounders, such as body mass index, dietary habits, or physical activity, which are all major risk factors for CRC. Besides, although many confounders can be controlled and adjusted for in the analysis, most of the included observational studies were based on retrospectively historical medical data. Thus, a complete elimination of bias on details was impossible. Third, pioglitazone and rosiglitazone are two different drugs for cancer risk. Pooling them together creates an obvious lack of drug-specific observational study. Fourth, this meta-analysis was based on published full-text articles; it may be affected by incomplete disclosure, with missing information on a lack of publication with opposite results. Fifth, this meta-analysis did not include randomized controlled trials (RCTs). Due to the small number of CRC cases and the short follow-up duration, previously published RCTs were not adequately powered to detect a significant association of TZDs use and CRC risk.[57],[58]


   Conclusion Top


In summary, this meta-analysis indicated that the use of TZDs is associated with a significantly decreased risk of CRC. TZDs might be considered as a novel approach in cancer adjuvant therapy. Considering the observed magnitude of CRC risk reduction associated with TZDs use was relatively modest, the number needed in order to treat to prevent one case of CRC would be large. Meanwhile, careful management of individual risk/benefit profiles is needed to limit the exposure to adverse effects of TZDs use. In the future, well-designed studies with larger cohorts are warranted to confirm the potential anti-neoplastic benefit for individuals with diabetes on TZDs treatment.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.  Back to cited text no. 1
[PUBMED]    
2.
Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol2005;3:587-94.  Back to cited text no. 2
[PUBMED]    
3.
Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?Am J Gastroenterol2011;106:1911-21; quiz 22.  Back to cited text no. 3
[PUBMED]    
4.
Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: A population-based, retrospective cohort study. Am J Gastroenterol2006;101:1872-9.  Back to cited text no. 4
[PUBMED]    
5.
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst2005;97:1679-87.  Back to cited text no. 5
[PUBMED]    
6.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care2010;33:1674-85.  Back to cited text no. 6
[PUBMED]    
7.
Giovannucci E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr2001;131:3109S-20S.  Back to cited text no. 7
[PUBMED]    
8.
Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics. Chemotherapy2007;53:233-56.  Back to cited text no. 8
[PUBMED]    
9.
Li JY, Yu T, Xia ZS, Chen GC, Yuan YH, Zhong W, et al. Enhanced proliferation in colorectal epithelium of patients with type 2 diabetes correlates with beta-catenin accumulation. J Diabetes Complications2014;28:689-97.  Back to cited text no. 9
[PUBMED]    
10.
Shafiei-Irannejad V, Samadi N, Salehi R, Yousefi B, Zarghami N. New Insights into Antidiabetic Drugs: Possible Applications in Cancer Treatment. Chem Biol Drug Design2017;90:1056-66.  Back to cited text no. 10
    
11.
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nature Med1998;4:1046-52.  Back to cited text no. 11
[PUBMED]    
12.
DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis1998;19:49-53.  Back to cited text no. 12
[PUBMED]    
13.
Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types.PPAR Res2008;2008:494161.  Back to cited text no. 13
[PUBMED]    
14.
Belfiore A, Genua M, Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: Implications for cancer.PPAR Res2009;2009:830501.  Back to cited text no. 14
[PUBMED]    
15.
Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol2004;5:419-29.  Back to cited text no. 15
[PUBMED]    
16.
Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology2003;124:361-7.  Back to cited text no. 16
[PUBMED]    
17.
Okumura T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol2010;45:1097-102.  Back to cited text no. 17
[PUBMED]    
18.
Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Investig2002;110:923-32.  Back to cited text no. 18
[PUBMED]    
19.
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature2000;405:421-4.  Back to cited text no. 19
[PUBMED]    
20.
Chiu SJ, Hsaio CH, Tseng HH, Su YH, Shih WL, Lee JW, et al. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun2010;394:774-9.  Back to cited text no. 20
[PUBMED]    
21.
Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology2012;55:1462-72.  Back to cited text no. 21
[PUBMED]    
22.
Chen SW, Tsan YT, Chen JD, Hsieh HI, Lee CH, Lin HH, et al. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based, case-control study. Diabetes Care2013;36:369-75.  Back to cited text no. 22
[PUBMED]    
23.
Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf2007;16:485-92.  Back to cited text no. 23
[PUBMED]    
24.
Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol2007;25:1476-81.  Back to cited text no. 24
[PUBMED]    
25.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.JAMA2000;283:2008-12.  Back to cited text no. 25
[PUBMED]    
26.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol2010;25:603-5.  Back to cited text no. 26
[PUBMED]    
27.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials1986;7:177-88.  Back to cited text no. 27
[PUBMED]    
28.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.BMJ2003;327:557-60.  Back to cited text no. 28
[PUBMED]    
29.
Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med 1995;14:395-411.  Back to cited text no. 29
[PUBMED]    
30.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50:1088-101.  Back to cited text no. 30
[PUBMED]    
31.
Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics2000;56:455-63.  Back to cited text no. 31
[PUBMED]    
32.
Htoo PT, Buse JB, Gokhale M, Marquis MA, Pate V, Sturmer T. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. Eur J Clin Pharmacol2016;72:1013-23.  Back to cited text no. 32
    
33.
Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes.JAMA2015;314:265-77.  Back to cited text no. 33
[PUBMED]    
34.
Sehdev A, Shih YC, Vekhter B, Bissonnette MB, Olopade OI, Polite BN. Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population. Cancer2015;121:1071-8.  Back to cited text no. 34
[PUBMED]    
35.
Valent F. Diabetes mellitus and cancer of the digestive organs: An Italian population-based cohort study. J Diabetes Complications2015;29:1056-61.  Back to cited text no. 35
[PUBMED]    
36.
Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based cohort study. J Clin Pharm Ther2014;39:354-60.  Back to cited text no. 36
[PUBMED]    
37.
Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia2012;55:1953-62.  Back to cited text no. 37
[PUBMED]    
38.
Ferrara A, Lewis JD, Quesenberry CP, Jr., Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care2011;34:923-9.  Back to cited text no. 38
    
39.
Oliveria SA, Koro CE, Yood MU, Sowell M. cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndrome Clin Res Rev2008;2:47-57.  Back to cited text no. 39
    
40.
Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab2001;86:5366-71.  Back to cited text no. 40
[PUBMED]    
41.
Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet2010;375:408-18.  Back to cited text no. 41
[PUBMED]    
42.
Weber MB, Oza-Frank R, Staimez LR, Ali MK, Narayan KM. Type 2 diabetes in Asians: Prevalence, risk factors, and effectiveness of behavioral intervention at individual and population levels. Annu Rev Nutr2012;32:417-39.  Back to cited text no. 42
[PUBMED]    
43.
Kao CH, Sun LM, Chen PC, Lin MC, Liang JA, Muo CH, et al. A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients?Ann Oncol2013;24:523-30.  Back to cited text no. 43
[PUBMED]    
44.
Chiu CC, Huang CC, Chen YC, Chen TJ, Liang Y, Lin SJ, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: A nationwide population-based study in Taiwan. Intern Med2013;52:939-46.  Back to cited text no. 44
[PUBMED]    
45.
Lai SW, Liao KF. Thiazolidinediones use and colorectal cancer risk. Diabetes Metab2013;39:88.  Back to cited text no. 45
[PUBMED]    
46.
Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis.CMAJ 2012;184:E675-83.  Back to cited text no. 46
[PUBMED]    
47.
Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol2014;78:258-73.  Back to cited text no. 47
[PUBMED]    
48.
Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci2005;87:322-7.  Back to cited text no. 48
[PUBMED]    
49.
Dominick MA, White MR, Sanderson TP, Van Vleet T, Cohen SM, Arnold LE, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol2006;34:903-20.  Back to cited text no. 49
[PUBMED]    
50.
Nemenoff RA. Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus “off-target” effectors. J Thorac Oncol2007;2:989-92.  Back to cited text no. 50
[PUBMED]    
51.
Cornell S. Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. J Am Pharmacists Assoc2017;57:261-5.  Back to cited text no. 51
    
52.
Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab2014;18:425-7.  Back to cited text no. 52
[PUBMED]    
53.
Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci2014;30:94-7.  Back to cited text no. 53
[PUBMED]    
54.
Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: A propensity score matched cohort study. Br J Clin Pharmacol2013;75:254-9.  Back to cited text no. 54
[PUBMED]    
55.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association Of Clinical Endocrinologists And American College Of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2017 Executive Summary. Endocr Pract2017;23:207-38.  Back to cited text no. 55
[PUBMED]    
56.
Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev2013;22:2258-68.  Back to cited text no. 56
[PUBMED]    
57.
Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia2010;53:1838-45.  Back to cited text no. 57
    
58.
Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn AR, Perez A. Observational follow-up of the PROactive study: A 6-year update. Diabetes Obesity Metab2014;16:63-74.  Back to cited text no. 58
    

Top
Correspondence Address:
Dr. Ting-Ting Hu
Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province
People's Republic of China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sjg.SJG_295_17

Rights and Permissions


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
  
 
  Search
 
  
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Patients and Methods
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed218    
    Printed5    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal